Pre-departure HIV Orientation Session A: Pre-ART Considerations 23 January, 2007 Royce C. Lin, MD Assistant Clinical Professor of Medicine University of.

Slides:



Advertisements
Similar presentations
June 2004 HITCH Training Slide Set #3 Special Considerations in Antiretroviral Therapy.
Advertisements

Treatment and Prevention of Opportunistic Infections: Options for the Caribbean Region Excerpted from presentation by Jonathan E. Kaplan, M.D.
Follow-up after training and supportive supervision The IMAI District Coordinator Course.
Role of The Home Based Carer Paediatric Palliative Care for Home Based Carers Funded by British High Commission, Pretoria, Small Grant Scheme.
Tuberculosis in Children: Prevention Module 10C - March 2010.
Pediatric Case Presentation BOGNON TANGUY Care Unit Children Exposed or Infected by HIV/AIDS Military Teaching Hospital - Cotonou - BENIN.
Acute Retroviral Syndrome
Improving Retention, Adherence, and Psychosocial Support within PMTCT Services: Implementation Workshop for Health Workers All slide illustrations by Petra.
Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities.
In the name of God Fariba Rezaeetalab Assistant Professor.
Cost-effectiveness of different starting criteria of antiretroviral therapy in Mexico. Caro Y., Colchero A., Valencia A., Bautista-Arredondo S., Sierra.
N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER 2014 IAS-USA Treatment Guidelines Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor.
Unit 10 Treating the Dually Infected Patient: B Family Case Botswana National Tuberculosis Programme Manual Training for Medical Officers.
Module 6: Routine HIV Testing of TB Patients. Learning Objectives Explain why TB suspects and patients should be routinely tested for HIV Summarize the.
Unit 5: IPT Isoniazid TB Preventive Therapy
Chronic HIV Infection Clinical Manifestations Opportunistic Infections O.I. Prophylaxis.
HIV in Suriname Ministry of Health Suriname M.Sigrid Mac Donald – Ottevanger, MD Focal point HIV Treatment and Care, NAP.
NYU Medical Grand Rounds Clinical Vignette Matthew B. Brown M.D. PGY-2 10/4/11 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.
1 Case year-old White UK male Lived with wife Living in urban area in England.
Pediatric HIV/AIDS: Orphans & Vulnerable Children.
Management of the Newly Diagnosed Patient. Jane Bruton Clinical Research Nurse Imperial College.
Unit 7 Treatment of TB: B Family Case Botswana National Tuberculosis Programme Manual Training for Medical Officers.
1 Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
IAS–USA When to Start Antiretroviral Therapy Constance A. Benson, MD Professor of Medicine University of California San Diego FINAL: Presented.
1 First Clinic Visit for Patients with HIV Infection HAIVN Harvard Medical School AIDS Initiative in Vietnam.
JNB/05 HIV/AIDS treatment - challenges in a remote rural area of Tanzania. Johan N. Bruun Department of Infectious Diseases Ullevål University Hospital.
Background There is uncertainty regarding the frequency, predictors, and outcomes of IRIS events Prior studies on IRIS have been limited to convenience.
Two Men with Extensive Genital Ulcer Disease Recent Cases at the Denver Metro Health Clinic.
IMAI Sequence of Care Task shifting, division of labor, and the role of non-clinicians on the care team.
Clinical Tracking and Management of HIV-Positive Children National Pediatric HIV Training 1.
1 Antiretroviral Therapy in HIV-infected Children HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection DR. S.K CHATURVEDI DR. KANUPRIYA CHATURVEDI.
1 Starting ART in the Context of Opportunistic Infections HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Office of Overseas Programming & Training Support (OPATS) Treatment Adherence HIV Care, Support, and Treatment.
Guidelines for the use of antiretroviral agents in HIV infections in Taiwan, revised in 2002 by Infectious Diseases Society of the ROC and Taiwan AIDS.
1 Monitoring The Patient on ARV Treatment HAIVN Harvard Medical School AIDS Initiative in Vietnam.
M. Ekstrand 1,2,3, A. Shet 2,4, S. Chandy 4, G. Singh 4, R. Shamsundar 4, V. Madhavan 5, S. Saravanan 5, N. Kumarasamy 5 1 University of California, San.
Clinicopathologic Conference Advanced Update in HIV Medicine and Clinical Research October 1, 2009 Tammy M. Meyers, BA, MBBCh (WITS), FCPaed (SA), Mmed,
Primary HIV-1 Infection Pathogenesis, Diagnosis, and Treatment Summary of Evidence Martin Markowitz M.D. Clinical Director and Staff Investigator Aaron.
Arnold School of Public Health Health Services, Policy, and Management 1 Drug Treatment Disparities Among African Americans Living with HIV/AIDS Carleen.
HIV/TB – Case Studies David Schlossberg, MD, FACP Medical Director, TB Control Program Philadelphia Department of Health.
ZIMBABWE AIDS CARE FOUNDATION NEWLANDS CLINIC Virological Outcomes in Adult Patients on Second Line ART, at Newlands Clinic Dr S. Bote.
HIV/TB Integration in a Network of Voluntary Counseling/Testing Centers in HAITI Reynold Grand’Pierre MD, Marie Suze Jacquet MD, Jean W. Pape MD PEPFAR.
1 HIV Clinical Staging HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Providing Treatment, Restoring Hope Secondary Prevention as part of HIV Clinical Care Martine Etienne, MPH, DrPH University of Maryland School of Medicine.
Module 3: Management of Patients on Antiretroviral Therapy Unit 2: Initiation and Monitoring of ART in Adults and Adolescents.
Prophylaxis of Opportunistic Infections
1 Communicating to Other Health Professionals About Your Patient: Doing Case Presentations HAIVN Harvard Medical School AIDS Initiative in Vietnam.
1 Management, Care for infants who were born from infected mothers HAIVN Harvard Medical School AIDS Initiatives in Vietnam.
HIVQUAL – ARV Management October 17, 2003 Saneese Stephen, RPA Kings County Hospital Center Center for H.O.P.E.
HAIVN Harvard Medical School AIDS Initiative in Vietnam
Sub module 3 Pre-ART and ART registers. Purpose of registers Key individual information for: Facilitating patient management by the identification of.
Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Human Immune Deficiency Virus Infection Dr Huda Taha Sep 2015.
N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER Major Changes to the HHS Adult and Adolescent HIV Treatment Guidelines: April 2015 Brian R. Wood, MD.
LEARNING MODULE TITLE SUBTITLE. HISTORY OF PRESENT ILLNESS An 18 year-old woman with no past medical history and no known risks for TB presents with several.
Response to Antiretroviral Treatment In an Ethiopian Hospital Samuel Hailemariam, MD, MPH; J Allen McCutchan, MD, MSc Meaza Demissie, MD, PMH, PHD; Alemayehu.
Tuberculosis in Children: Treatment and Monitoring Module 10B - March 2010.
Communicating with Patients and Providers HIV Care and ART: A Course for Pharmacists.
Daniel Meressa, M.D. Global Health Committee St. Peter’s Hospital
2017 Key Considerations for adolescents and children & Key populations
Module 4: Role Playing and Case Discussions
Validating Definitions of Antiretroviral Treatment Failure in Malawi
Pharmacokinetics: HIV Drugs
Dr Dawood Quiz questions.
World Health Organization
The role of CD4 in patient monitoring Amsterdam July 2018
When to START During an OI
Management of Immune Reconstitution Inflammatory Syndrome (IRIS)
Anthony D Harries Ministry of Health, Malawi
Presentation transcript:

Pre-departure HIV Orientation Session A: Pre-ART Considerations 23 January, 2007 Royce C. Lin, MD Assistant Clinical Professor of Medicine University of California, San Francisco Director, AIDS Consult Service San Francisco General Hospital Deputy Director, ASPIRE Positive Health Program, SFGH

GOALS Overview: Pre-ART considerations Overview: Pre-ART considerations Medical indications Medical indications WHO guidelines WHO guidelines Kenyan national guidelines Kenyan national guidelines US DHHS guidelines US DHHS guidelines WHO Staging system WHO Staging system Cotrimoxazole prophylaxis Cotrimoxazole prophylaxis Adherence issues Adherence issues

Pre-ART considerations: US Initial Visit F/U Visit HAART F/U Visit Full HPI, PMH Full Lab Counseling (tx, support) Establish relationship Adjunct services (social, insurance) Vaccinations Problem list, Px, Rx Follow CD4 decline Prep ART as CD4 <350 Choose regimen with pt input Adherence counseling/support Monitor toxicity Therapy switch as needed

Pre-ART considerations: RLS Initial Visit F/U visit HAART F/U Visit HPI, PMH (form/algorithm driven) Select Labs (baseline + ?TB, preg) WHO staging (triage ART) Counseling (x 3. Peer groups support) Adjunct services (nutrition, HBC) Cotrimoxazole Problem list, Px, Rx (algorithm-driven) See CD4 result With WHO, assess ART eligibility Adherence counseling x 3 if ART Cotrimoxazole, other prevention All get Triomune, unless contraindication Pregnancy? TB? Monitor toxicity (TB, preg, IRIS) Therapy switch as needed

When to Start HAART?

 All who have a CD4+ count ≤ 200 cells/mm 3, regardless of stage of illness  All who are in WHO stage IV clinical criteria, regardless of CD4+ cell count  Consider those who are in WHO Stage III clinical criteria and have CD4 cell counts ≤ 350/mm 3 Note! The patient must have expressed willingness and be ready to start therapy When to Start Therapy in adults Kenyan Guidelines

U.S. DHHS Guidelines Summary: ART recommended for… All with history of AIDS-defining illness, regardless of CD4 count All with history of AIDS-defining illness, regardless of CD4 count All with CD4<200 All with CD4<200 CD should be offered therapy CD should be offered therapy CD4>350 CD4>350 Most clinicians defer therapy regardless of VL Most clinicians defer therapy regardless of VL Some offer therapy if VL>100,000 Some offer therapy if VL>100,000

Perform WHO clinical staging Confirmed HIV + Individual WHO Clinical Stage 1 WHO Clinical Stage 2 WHO Clinical Stage 3 WHO Clinical Stage 4 Perform CD4+ T cell count Eligible for ART regardless of CD4 count CD4: <200 cells/mm 3 Do NOT initiative ART. Monitor patient regularly CD4: cells/mm 3 CD4: >350 cells/mm 3 Eligible for ART regardless WHO Clinical stage Consider ART ONLY if in WHO clinical stage III

WHO Clinical Staging

WHO Clinical Staging System for Adults and Adolescents

Stage I Asymptomatic

Stage II Not yet AIDS, but getting sick CD4 usually

Courtesy of Jackie Dolev, M.D. Department of Dermatology University of California, San Francisco

Prurigo

Herpes Zoster-Shingles

Stage III Early AIDS CD4 usually <200

Stage III Pulmonary TB Severe bacterial infections Bacterial pneumonia Pyomyositis Performance scale 3 Bedridden <50% in past month

Stage IV Late AIDS CD4 usually <

Other Stage IV Extrapulmonary TB Cryptococcal Meningitis Toxoplasmosis Esophoegeal candidiasis MAC CMV Retinitis HSV in mucocutaneous site Progressive Multifocal Leukoencephalopathy AIDS Dementia Complex Weight loss >10% and bedbound >50%

PSYCHOSOCIAL Contraindications OI Adherence? clinical signs Family and support? CD4 MEDICAL Indications Substance abuse

Who should get ART first? A. Female University Student A. Female University Student CD Thrush. Treated with clotrimazole CD Thrush. Treated with clotrimazole Family knows and is supportive Family knows and is supportive B. Successful Businessman B. Successful Businessman CD Very high VL (>500,000) CD Very high VL (>500,000) Diagnosed 1 week, anxious, demands immediate ART. Reluctant to disclose to spouse. Diagnosed 1 week, anxious, demands immediate ART. Reluctant to disclose to spouse. C. Disbelieving Rural Woman C. Disbelieving Rural Woman CD4 47. Bacterial pneumonia. Cutaneous KS CD4 47. Bacterial pneumonia. Cutaneous KS Skeptical about her AIDS diagnosis. Skeptical about her AIDS diagnosis.

When to Start: PART II Medical consideration only half of the equation Medical consideration only half of the equation Patient readiness EQUALLY important Patient readiness EQUALLY important Therapy quickly FAILS if suboptimal adherence Therapy quickly FAILS if suboptimal adherence >95% Adherence needed! >95% Adherence needed! Especially important with Triomune! Especially important with Triomune! Once first-line fails, second-line agents may not be effective and are more toxic Once first-line fails, second-line agents may not be effective and are more toxic BETTER TO WAIT AND START WHEN PATIENT IS TRULY READY BETTER TO WAIT AND START WHEN PATIENT IS TRULY READY

Adherence A major determinant of degree and duration of viral suppression A major determinant of degree and duration of viral suppression Poor adherence associated with virologic failure Poor adherence associated with virologic failure What percentage adherence is most strongly-associated with emergence of viral resistance? What percentage adherence is most strongly-associated with emergence of viral resistance? Optimal suppression requires % adherence Optimal suppression requires % adherence Even MORE important in resource-limited settings given lack of access to resistance testing, limited salvage options Even MORE important in resource-limited settings given lack of access to resistance testing, limited salvage options Suboptimal adherence is common Suboptimal adherence is common

Predictors of Inadequate Adherence Poor clinician-patient relationship Poor clinician-patient relationship Active drug use or alcoholism Active drug use or alcoholism Unstable housing Unstable housing Mental illness (especially depression) Mental illness (especially depression) Major life crises Major life crises Lack of patient education Lack of patient education Lack of patient access to medical care Lack of patient access to medical care Medication adverse effects Medication adverse effects Fear of medication adverse effects Fear of medication adverse effects

Predictors of Good Adherence Emotional and practical supports Emotional and practical supports Family, friends, social support Family, friends, social support Importance of social work, CBOs Importance of social work, CBOs Understanding the importance of adherence Understanding the importance of adherence Belief in efficacy of medications Belief in efficacy of medications Keeping clinic appointments Keeping clinic appointments Feeling comfortable taking medications in front of others Feeling comfortable taking medications in front of others Convenience of regimen Convenience of regimen Consideration of patient preferences in constructing an antiretroviral regimen Consideration of patient preferences in constructing an antiretroviral regimen

Predictors of Inadequate Adherence Age, race, sex, educational level, socioeconomic status, and a past history of alcoholism or drug use do NOT reliably predict suboptimal adherence. Age, race, sex, educational level, socioeconomic status, and a past history of alcoholism or drug use do NOT reliably predict suboptimal adherence. Higher socioeconomic status and higher education levels and lack of history of drug use do NOT reliably predict optimal adherence. Higher socioeconomic status and higher education levels and lack of history of drug use do NOT reliably predict optimal adherence.

Practicum: Case Discussions

Case scenario #1 35 yo woman from Kisumu 35 yo woman from Kisumu Tested HIV+ recently Tested HIV+ recently Comes to you for first visit in clinic Comes to you for first visit in clinic Wants to know what she should do Wants to know what she should do Physically well, no symptoms Physically well, no symptoms Baseline weight 68kg. Now 66kg. Baseline weight 68kg. Now 66kg. What WHO clinical stage is she? What WHO clinical stage is she? What else do you want to know? What else do you want to know? What do you want to do today? What do you want to do today?

Case scenario #1 1 year later, pt presents to casualty with 1 month hx of dry, non-productive cough. 1 year later, pt presents to casualty with 1 month hx of dry, non-productive cough. Hx: Increasing shortness of breath Hx: Increasing shortness of breath Scant sputum. No hemoptysis Scant sputum. No hemoptysis Weight: 59kg RR 32 Weight: 59kg RR 32 CXR: diffuse, patchy bilateral infiltrates. CXR: diffuse, patchy bilateral infiltrates. Exam: Diffuse rales, L>R. Oral thrush Exam: Diffuse rales, L>R. Oral thrush Pt is admitted to the ward Pt is admitted to the ward Has his clinical stage changed? Has his clinical stage changed? What stage do you guess him to be in now? What stage do you guess him to be in now? What do you want to do now? What do you want to do now?

Case Scenario #1 Hospital course Hospital course Sputum x 3: smear negative for AFB Sputum x 3: smear negative for AFB Started empirically on amoxicillin without improvement. Started empirically on amoxicillin without improvement. TMP/SMX begun (for presumed PCP) TMP/SMX begun (for presumed PCP) 5-days later: decreased SOB, cough 5-days later: decreased SOB, cough Discharged. Complete Rx at home Discharged. Complete Rx at home 5 days later (day#10 rx) 5 days later (day#10 rx) Seen in clinic Seen in clinic Still on PCP treatment. Finished amoxicillin Still on PCP treatment. Finished amoxicillin CD4 comes back: 178 CD4 comes back: 178 Feeling much better, slight residual cough Feeling much better, slight residual cough Weight 57kg. RR 18. Rales resolved. Weight 57kg. RR 18. Rales resolved. When do you want to start ART? When do you want to start ART?

Case Scenario #1 Who wants to start ART today? Who wants to start ART today? Does he meet medical indications to start ART? Does he meet medical indications to start ART? By which criteria? By which criteria? What are other considerations? What are other considerations? What would you do at this visit? What would you do at this visit? When is the optimal time to start ART? When is the optimal time to start ART?

Teaching points Wait until OI is treated Wait until OI is treated Increased overlapping toxicity Increased overlapping toxicity Increased risk of immune reconstitution syndrome Increased risk of immune reconstitution syndrome Prepare patient for ART Prepare patient for ART Assess psychosocial readiness Assess psychosocial readiness Establish relationship Establish relationship Involve entire care team Involve entire care team Good preparation = Successful therapy Good preparation = Successful therapy

Summary Medical Indications Medical Indications Any AIDS-defining condition Any AIDS-defining condition Any OI Any OI WHO Stage IV WHO Stage IV CD4<200 CD4<200 WHO, US guidelines agree WHO, US guidelines agree Psychosocial contraindications Psychosocial contraindications Factors of adherence Factors of adherence Belief systems Belief systems Role of social work, CBO, support Role of social work, CBO, support Balance between the two determines when to start ART Balance between the two determines when to start ART Careful consideration of both sides of equation leads to optimal chance at successful suppression of HIV. Careful consideration of both sides of equation leads to optimal chance at successful suppression of HIV.